Merck & Company, Inc. (NYSE:MRK) Stock Rating Reaffirmed by BMO Capital Markets

Merck & Company, Inc. (NYSE:MRK)‘s stock had its “buy” rating restated by equities researchers at BMO Capital Markets in a report issued on Friday, September 8th. They currently have a $72.00 price objective on the stock. BMO Capital Markets’ target price points to a potential upside of 10.55% from the company’s previous close.

Several other research firms have also issued reports on MRK. Goldman Sachs Group Inc reiterated a “neutral” rating and issued a $74.00 target price (up previously from $70.00) on shares of Merck & in a research note on Thursday, July 27th. Citigroup Inc. set a $65.00 target price on shares of Merck & and gave the stock a “hold” rating in a research note on Wednesday, July 5th. Zacks Investment Research upgraded shares of Merck & from a “hold” rating to a “buy” rating and set a $73.00 target price for the company in a research note on Friday, May 26th. BidaskClub lowered shares of Merck & from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Finally, Piper Jaffray Companies set a $70.00 target price on shares of Merck & and gave the stock a “buy” rating in a research note on Saturday, July 29th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $70.00.

Merck & (NYSE MRK) traded up 0.05% during midday trading on Friday, hitting $65.16. The stock had a trading volume of 4,600,985 shares. Merck & has a 52 week low of $58.29 and a 52 week high of $66.80. The stock’s 50 day moving average price is $63.52 and its 200-day moving average price is $63.68. The company has a market cap of $177.71 billion, a PE ratio of 35.28 and a beta of 0.81.

Merck & (NYSE:MRK) last announced its quarterly earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, beating the Zacks’ consensus estimate of $0.87 by $0.14. The business had revenue of $9.93 billion during the quarter, compared to analyst estimates of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. Merck &’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.93 EPS. Equities research analysts predict that Merck & will post $3.87 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another site, it was stolen and reposted in violation of US and international copyright law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2017/09/25/merck-company-inc-mrk-earns-buy-rating-from-bmo-capital-markets.html.

Institutional investors have recently made changes to their positions in the company. Perennial Advisors LLC raised its stake in Merck & by 10.7% in the second quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after purchasing an additional 157 shares in the last quarter. Stelac Advisory Services LLC purchased a new stake in Merck & in the second quarter valued at approximately $104,000. Vigilant Capital Management LLC raised its stake in Merck & by 16.7% in the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after purchasing an additional 250 shares in the last quarter. Cascade Investment Advisors Inc. raised its stake in Merck & by 15.5% in the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after purchasing an additional 232 shares in the last quarter. Finally, Solaris Asset Management LLC raised its stake in Merck & by 6.3% in the second quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after purchasing an additional 115 shares in the last quarter. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Analyst Recommendations for Merck & (NYSE:MRK)




Receive News & Ratings for Merck & Company Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Merck & Company Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

3 + 8 =